P3-130: A large Spanish experience with erlotinib in advanced non–small cell lung cancer

Abstract

P=0.005) was significantly associated with the higher response rate to gefitinib. Progression-free survival (6.6 vs. 3.3 months; p=0.246) and overall survival (8.1 vs. 8.6 months; p=0.397) were similar between patients with EGFR mutations and those with wild-type EGFR. Conclusion: Clinical response to gefitinib in this study was linked to the presence of EGFR mutations. Given the limitation of small sample size, EGFR mutations were not associated with the specific clinical predictors for gefitinib responsiveness.

Response Rate Is Associated with Prolonged Survival in Patients with Advanced Non-small Cell Lung Cancer Treated with Gefitinib or Erlotinib

“…b One study 25 was excluded because it did not have detail information about performance status. c Seven studies 10,11,14,15,19,26,28 were excluded because they contained both chemotherapy-naïve patients and chemotherapy-received patients.…”